Companies test antibody drugs to treat, prevent COVID-19

  • 📰 CTVNews
  • ⏱ Reading Time:
  • 48 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 99%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there's an infection so it makes antibodies and remembers how to do that if the real bug turns up.

They're also being tested as treatments, to help the immune system and prevent severe symptoms or death. One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results. "The success with our Ebola program gives us some confidence that we can potentially do this again," said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.

Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever. Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and "you will have less doses available." If a single antibody works, "we can treat twice as many people," he said.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 1. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Companies test antibody drugs to treat COVID-19 while push for vaccine continuesThese drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection
출처: globeandmail - 🏆 5. / 92 더 많은 것을 읽으십시오 »